KalVista Pharmaceuticals Inc

NASDAQ:KALV  
28.77
-0.13 (-0.45%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)698.75M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$1.2 Million
Adjusted EPS-$0.56
See more estimates
10-Day MA$27.92
50-Day MA$25.93
200-Day MA$21.63
See more pivots

KalVista Pharmaceuticals Inc Stock, NASDAQ:KALV

55 Cambridge Parkway, Suite 901 East, Cambridge, Massachusetts 02142
United States of America
Phone: +1.857.999.0075
Number of Employees: 56

Description

KalVista Pharmaceuticals, Inc. is a clinical stage pharmaceutical company, which engages in the discovery, development, and commercialization of small molecule protease inhibitors. Its product candidates are inhibitors of plasma kallikrein being developed for two indications: hereditary angioedema (HAE) and diabetic macular edema (DME). The company was founded by T. Andrew Crockett, Edward P. Feener, and Lloyd Paul Aiello on March 26, 2004 and is headquartered in Cambridge, MA.